ClinicalTrials.gg
Status unknownNCT03536377Updated Mar 28, 2019

Implementation of a Very Low Calorie Diet for Remission of Type 2 Diabetes in the Community

An interventional study of very low calorie liquid diet in Diabetes Mellitus Type 2 in Obese, sponsored by The University of The West Indies. Status unknown at 4 sites in Barbados. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-28.

Sponsored by The University of The West Indies · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Study summary

The complications associated with uncontrolled type-2 diabetes mellitus (T2DM) are numerous; reducing the quality of life for the patient and consuming a considerable portion of healthcare finances.

The Health of the Nation (HotN) 2011 study reported that 50% of the Barbadian population >65years old had a diagnosis of T2DM and that two-thirds of the population were overweight - which is a risk factor for the development of T2DM.

Encouraged by the success of the Counterpoint study in the United Kingdom (UK), the Barbados Diabetes Reversal Study 1 (BDRS1) was established using a similar protocol; the aim of which was to evaluate the feasibility of implementing a very low calorie diet to reverse T2DM in Barbados. At the end of the 8-week intervention period, the 25 participants had achieved an average weight loss of 10.1kg (22lbs). This was accompanied by an increase in the number of participants whose fasting blood sugars were now within normal range despite being off of their diabetes medication; and a decrease in the number of participants taking blood pressure medication. Participants transitioned to a solid diet over a 4-week period, with guidance on health dietary habits and regular exercise routines. The benefits accrued during the intervention phase were preserved at the end of the transition period.

We now propose the Barbados Diabetes Remission Study 2 (BDRS2) as a sustainable community intervention - utilizing the local church as the community site. We hypothesize that this will enhance reach while reducing the cost of the study and will also facilitate the structures necessary for the social support of the participant.

02

Conditions studied

  • Diabetes Mellitus Type 2 in Obese

Keywords

  • Diabetes Mellitus Remission
  • Prediabetic State
  • caloric restriction
  • weight loss
  • diet
  • Barbados
03

In context

Prediabetic State

1,021 studies on the registry are indexed under Prediabetic State; 242 are open to participants now.

This study's planned enrollment of 100 is above the median of 66 across 861 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

The University of The West Indies is the lead sponsor of 64 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 - 70 years old, all ethnicities
  • Diagnosis of T2DM for \<6 years as defined by the American Diabetes Association
  • Diagnosis of pre-diabetes as defined by the American Diabetes Association
  • Body Mass index (BMI) of 27 kg/m2 and over

Exclusion criteria

Exclusion Criteria:

  • Insulin use
  • Substance abuse
  • Current cancer diagnosis
  • myocardial infarction within last 6 month
  • learning difficulties
  • current treatment with anti-obesity drugs
  • diagnosed eating disorder or purging
  • HbA1c > 10%
  • pregnant/considering pregnancy
  • evidence of liver disease (including liver enzymes > 3 times above normal values)
  • evidence of renal disease (creatinine of > 150 mmol/l)
  • persons who have required hospitalisation for depression, or are on antipsychotic drugs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    very low calorie liquid diet

    Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence

    Other: very low calorie liquid diet

Interventions

  • Othervery low calorie liquid diet

    Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material

06

What researchers measure

Primary outcomes

  1. change in weight

    Time frame: enrolment, 12 weeks, 6 mths and 1 year

  2. change in fasting glucose

    Time frame: Enrolment, 12 weeks, 6 months, 1 year

  3. change in Hba1C

    Time frame: Enrolment, 12 weeks, 6 months, 1 year

Secondary outcomes

  1. change in waist circumference

    Time frame: Enrolment, 12 weeks, 6 months, 1 year

  2. change in blood pressure

    both the systolic and diastolic pressures will be measured

    Time frame: Enrolment, 12 weeks, 6 months, 1 year

  3. change in blood pressure medication

    Time frame: weekly for the first 12 weeks

07

Study locations

3 of 4 sites recruiting
  • Abundant Life Assembly
    Bridgetown, Bank Hall, Saint Michael, Barbados
    Not yet recruiting
  • Ellerton Wesleyan Church
    Bridgetown, Ellerton, Saint George, Barbados
    Recruiting
  • River Road New Testament Church of God
    Bridgetown, River Road, Saint Michael, Barbados
    Recruiting
  • Mount of Praise Wesleyan Church
    Bridgetown, Tudor Bridge, Saint Michael, Barbados
    Recruiting
08

References and documents

Publications

  • Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011 Oct;54(10):2506-14. doi: 10.1007/s00125-011-2204-7. Epub 2011 Jun 9. PubMed 21656330 ↗
  • Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-551. doi: 10.1016/S0140-6736(17)33102-1. Epub 2017 Dec 5. PubMed 29221645 ↗
  • Unwin N, Rose AMC, George KS, Hambleton IR, Howitt C. The Barbados Health of the Nation Survey: Core Findings. Chronic Disease Research Centre, The University of the West Indies and the Barbados Ministry of Health: St Michael, Barbados, January 2015; 48 pp
  • Karen Bynoe, Maddy Murphy, Charles Taylor, Andre Greenidge, Melissa Abed, Nigel Unwin. The Barbados Diabetes Reversal Study Preliminary Results https://www.cavehill.uwi.edu/fms/resources/cme/78th-cme-presentations/karen-bynoe-barbados-diabetes-reversal-study.aspx
  • Quimby KR, Murphy MM, Harewood H, Howitt C, Hambleton I, Jeyaseelan SM, Greaves N, Sobers N. Adaptation of a community-based type-2 diabetes mellitus remission intervention during COVID-19: empowering persons living with diabetes to take control. Implement Sci Commun. 2022 Jan 24;3(1):5. doi: 10.1186/s43058-022-00255-9. PubMed 35074020 ↗
  • Quimby KR, Sobers N, George C, Greaves N, Browman-Jones F, Samuels TA. Implementation of a community-based low-calorie dietary intervention for the induction of type-2 diabetes and pre-diabetes remission: a feasibility study utilising a type 2 hybrid design. Implement Sci Commun. 2021 Aug 28;2(1):95. doi: 10.1186/s43058-021-00196-9. PubMed 34454636 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Aug 2020, 18 months after the start.

Of 415 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 18 months is below that.

Counting every sponsor, half of 466 studies reached it within 24 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
May 24, 2018
StartActual
Feb 11, 2019
Primary completionEst.
Aug 2020
CompletionEst.
Dec 2020
Last update
Mar 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03536377
Lead sponsor
The University of The West Indies
Responsible party
Sponsor
First posted
May 24, 2018
Start date
Feb 11, 2019
Primary completion
Aug 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Mar 28, 2019

Study contacts

Kim R Quimby, MBBS, PhD
Contact
kim.quimby@cavehill.wui.edu
12464266416
T Alafia Samuels, MBBS, PhD
study chair · George Alleyne Chronic Disease Research Centre, The University of the West Indies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion